Cisplatin with gemcitabine

Vokes EE, Leopold KA, Herndon JE, et al. CALGB Study 9431 Arandomized phase study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy and concomitant chemoradiotherapy for unresectable stage III non-small cell lung cancer. Lung Cancer 2000 29(Sl) 49(Abstract 158). 

Giaccone, G. et al., Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer a phase 111 trial-lNTACT, /. Clin. Oncol., 22, 777-784, 2004. 

Goss G, Lochrin C, Perry G, et al. A phase I study of gemcitabine and Cisplatin with concurrent curative irradiation in Stage III Non-small cell lung cancer (NSCLC). Pro Am Soc Clin Oncol 1999 18 abstract 1986. 

Fossella FV, Zinner RG, Komaki R, et al. Gemcitabine with concurrent chest radiation followed by consolidation chemotherapy with gemcitabine plus cisplatin A phase I trial for patients with stage III non-small cell lung cancer. Lung Cancer 2000 29(Suppl 1) 111 (abstract 368). 

Lord RV, Brabender J, Gandara D et al. Low ERCCl expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002 8 2286-2291. 

Goss G et al (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer a study of the national cancer institute of Canada clinical trials group. Eur J Cancer 45 782-788... 

Larotaxel (XRP-9881, RPR 109881A) 59 (Sanofi-Aventis) is undergoing Phase III trials in patients with advanced pancreatic cancer who had been previously treated with gemcitabine, as well as in combination with cisplatin to treat locally advanced/metastatic urothelial tract or bladder cancer.124 A Phase III trial for the treatment of advanced breast cancer has been completed. Larotaxel 59129>130 js a semi-synthetic derivative of 10-deacetyl baccatin III with a docetaxel-like side chain that has a low affinity for the P-glycoprotein drug efflux pump, an efflux mechanism that diminishes the effectiveness of the marketed drugs paclitaxel 60 and docetaxel. Importantly, this low affinity should enable larotaxel 59 to be effective in tumours resistant to paclitaxel 60... 

Adjei, A.A., Croghan, G.A., Erlichman, C., Marks, R.S., Reid, J.M., Sloan, J.A., Pitot, H. C., Alberts, S.R., Goldberg, R.M., Hanson, L.J., Bruzek, L.M., Atherton, P., etal. (2003). A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 9 2520-2526. 

Siegel-Lakhai, W.S., Crul, M., Zhang, S., Sparidans, R.W., Pluim, D., Howes, A., Solanki, B., Beijnen, J.H., and Schellens, J.H. (2005). Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced sohd tumours. Br J Cancer 93 1222-1229. 

Villalona-Calero MA, Ritch P, Figueroa JA, et al. A phase l/ll study of LY900003, an antisense inhibitor of protein kinase Ca, in combination with cisplatin and gemcitabine in patients with advanced nonsmall-cell lung cancer. Clin Cancer Res 2004 1 0(1 8 Pt 1 ) 6086-6093. 

Vansteenkiste J, Canon JL, Riska H, et al. Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic nonsmall-cell lung cancer. Invest New Drugs 2005 23 263-269. 

Gatzemeier U, Pluzanska A, Szczesna A et al. (2007) Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25 1545-1552... 

Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non-squamous non-small-cell lung cancer AVAIL. J Clin Oncol 2009 27(8) 1227-34. 

Combination studies of olaparib are being explored clinically with a number of agents, including irinotecan, dacarbazine, carboplatin, gemcitabine, doxorubicin, cisplatin, and topotecan. 

Four to six cycles of doublet chemotherapy with cisplatin or carboplatin plus docetaxel, gemcitabine, paclitaxel, or vinorelbine are recommended as first-line chemotherapy for patients with unresectable stage III or IV NSCLC. No combination was found to be superior tolerance of expected toxicities may contribute to the decision. 

Kaufman D, Raghavan D, Carducci M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000 9 1921-1927. 

---